Compass Group PLC Sponsored ADR (CMPGY)
atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy' for analysts at Jefferies, who continue to see significant upside ahead for the company following the release of new data from Compass Pathways (NASDAQ:CMPS)' late-stage trial of its synthetic psilocybin COMP360 in treatment-resistant depression (TRD). Compass Pathways on Monday reported that its COMP360 therapy reached its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo.
Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint
Compass Pathways (NASDAQ:CMPS) has reported positive results from its Phase 3 trial of its synthetic formulation of psilocybin, COMP360, in patients with treatment-resistant depression (TRD), with the trial meeting its primary endpoint. A single 25 mg dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo, with a mean difference of 3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6.
Compass Pathways' depression drug succeeds late-stage trial
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
Compass: Harnessing Your Technological Potential Before It's Late
Compass is gaining market share by empowering agents with advanced technology, leading to record agent growth even in a tough real estate market. Despite revenue reliance on transaction fees, Compass demonstrates stable revenues, growing free cash flow, and a rapidly improving balance sheet. The company is nearing profitability, with net losses shrinking and adjusted EBITDA turning positive, reflecting operational efficiency and effective cost control.
Compass Diversified Takes Decisive Steps Amid Lugano Probe, Stock Dips
CODI suspends payouts, cuts fees and restricts Lugano investments amid probe. Its shares plummet 10.2% after trading hours.
Compass Group eyes margin boost as vending machines quietly power ahead
Compass Group PLC (LSE:CPG) has long been seen as a reliable operator, benefiting from steady contract wins and its scale in procurement. But according to UBS, there is more going on under the bonnet, and it could help push profit margins higher than many expect.
Compass: Building A Real Estate Goliath While The Industry Is Weak
Compass is outperforming the shrinking real estate industry, growing market share both organically and through acquisitions, despite challenging macro conditions. Innovative product offerings and international expansion, including the Christie's acquisition, are driving growth and attracting agents and sellers to the Compass platform. Profitability is improving meaningfully, with rising attach rates for title, and escrow services and disciplined operating expense growth supporting adjusted EBITDA gains.
Compass Diversified: Overreaction To Its Internal Investigation Creates Potential Buying Opportunity
Compass Diversified (CODI) dropped 62% on May 8 due to an internal investigation of subsidiary Lugano Holding. It has recovered slightly since. Despite the bad news, I believe the market overreacted, presenting an opportunity for risk-tolerant investors to profit from a potential turnaround. The issue was self-reported and contained, which is better than if it had been discovered by external regulators or short sellers.
Compass Group falls as growth moderates and prospects for buybacks 'on pause', say analysts
Compass Group PLC (LSE:CPG) shares fell 2.9% after the catering giant reported half-year results that contained slightly slower growth in the past quarter. Organic growth moderated to 8.5% in the six months to March 2025 from 9.2% in the first quarter, with guidance for 7.5% growth over the full year remaining unchanged, including net new business of 4.4%.
Compass Group heads south despite solid half-year results
Compass Group PLC (LSE:CPG) shares fell 3.4% despite the catering group reporting first-half results in line with expectations, hiking the dividend 9% and maintaining its full-year outlook. Revenue came to $22.6 billion for the six months ended 31 March 2025, an increase of 8.8% compared to the same period last year.
Compass Group Backs Full-Year Guidance as Earning Rise
The catering contractor said its pretax profit for the six months ended March 31 rose to $1.28 billion from $1.20 billion in the same period a year prior.
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers
Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio.
